Invivyd stock reports positive LIBERTY safety data

Invivyd stock reports positive LIBERTY Phase 3 safety data after GlobeNewswire reported the companys September 29, 2026 topline results for VYD2311. The six-day safety comparison gives the program a clear clinical reference point, while the next major checkpoint is scheduled for October.

LIBERTY shows lower event rates

In the 210-person LIBERTY study, 56.5 percent of participants receiving VYD2311 experienced a treatment-emergent adverse event, injection-site reaction or hypersensitivity reaction during the first six days. The corresponding rate for the mRNA vaccine arm was 91.4 percent, with a p-value below 0.0001, according to GlobeNewswire.

The systemic adverse-event rate was 44.1 percent for VYD2311 versus 68.1 percent for the vaccine over the same six-day period. At 56 days, the combined event rate was 60.9 percent for VYD2311 and 91.4 percent for the vaccine, preserving the numerical gap at the longer follow-up point.

October data shape the filing path

Invivyd plans to use LIBERTY together with the ongoing DECLARATION trial in a planned Biologics License Application under the FDA Accelerated Approval Program. The company expects DECLARATION safety and immunogenicity data in October 2026, while clinical efficacy events are intended to remain blinded for a later confirmatory analysis, as StockTitan reported on September 29, 2026.

The combination arm also produced a 50.0 percent systemic adverse-event rate versus 68.1 percent for vaccine alone. Neutralizing titers increased in the combination setting, but the October DECLARATION readout remains the more important regulatory test because LIBERTY was a safety and immunogenicity study rather than the pivotal efficacy trial.

Nasdaq valuation stays speculative

IVVD was trading at USD 0.86 on Nasdaq on September 29, 2026 at 3:53 p.m. ET. Its market capitalization was USD 252.7 million, and the 52-week range was USD 0.53 to USD 3.07, placing the clinical program at an early-stage valuation with substantial development risk.